JP2024525613A5 - - Google Patents
Info
- Publication number
- JP2024525613A5 JP2024525613A5 JP2024500492A JP2024500492A JP2024525613A5 JP 2024525613 A5 JP2024525613 A5 JP 2024525613A5 JP 2024500492 A JP2024500492 A JP 2024500492A JP 2024500492 A JP2024500492 A JP 2024500492A JP 2024525613 A5 JP2024525613 A5 JP 2024525613A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- optionally
- sequence
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220016P | 2021-07-09 | 2021-07-09 | |
| US63/220,016 | 2021-07-09 | ||
| US202263316466P | 2022-03-04 | 2022-03-04 | |
| US63/316,466 | 2022-03-04 | ||
| PCT/US2022/073541 WO2023283624A2 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525613A JP2024525613A (ja) | 2024-07-12 |
| JP2024525613A5 true JP2024525613A5 (OSRAM) | 2025-07-17 |
Family
ID=84802101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500492A Pending JP2024525613A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368296A1 (OSRAM) |
| EP (1) | EP4366741A4 (OSRAM) |
| JP (1) | JP2024525613A (OSRAM) |
| KR (1) | KR20240035824A (OSRAM) |
| AU (1) | AU2022309238A1 (OSRAM) |
| CA (1) | CA3226367A1 (OSRAM) |
| IL (1) | IL309912A (OSRAM) |
| MX (1) | MX2024000492A (OSRAM) |
| WO (1) | WO2023283624A2 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| TW202442246A (zh) | 2023-04-27 | 2024-11-01 | 美商薩羅塔治療公司 | 用於治療慢性腎病之反義寡聚物 |
| TW202448485A (zh) * | 2023-05-05 | 2024-12-16 | 美商拜奧馬林製藥公司 | 肌萎縮蛋白外顯子跳躍寡核苷酸 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| AU2024362420A1 (en) | 2023-10-18 | 2026-04-23 | Murdoch University | Antisense oligomers for treatment of centronuclear myopathies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005058244A2 (en) * | 2003-12-15 | 2005-06-30 | Alexion Pharmaceuticals, Inc. | Novel anti-dc-sign antibodies |
| PL1766010T3 (pl) * | 2004-06-28 | 2011-07-29 | Univ Western Australia | Antysensowne oligonukleotydy do indukcji pominięcia egzonu i sposoby ich zastosowania |
| WO2008073300A2 (en) * | 2006-12-08 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
| PE20170917A1 (es) * | 2010-12-20 | 2017-07-12 | Genentech Inc | Anticuerpos anti-mesotelina e inmunoconjugados |
| BR112014003999A2 (pt) * | 2011-08-23 | 2017-06-13 | Roche Glycart Ag | anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp |
| WO2015134365A2 (en) * | 2014-03-03 | 2015-09-11 | Acharjee Sujata | Chimeric dystrophin-vsv-g-protein to treat dystrophinopathies |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| LT3433280T (lt) * | 2016-03-22 | 2023-07-10 | F. Hoffmann-La Roche Ag | Proteazės aktyvuojamos t ląstelei bispecifinės molekulės |
| MA50269A (fr) * | 2017-09-22 | 2020-07-29 | Avidity Biosciences Inc | Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon |
| JP7611825B2 (ja) * | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| MX2021001282A (es) * | 2018-08-02 | 2021-07-15 | Dyne Therapeutics Inc | Complejos dirigidos al músculo y sus usos. |
| CA3137715A1 (en) * | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| KR20220125802A (ko) * | 2020-01-10 | 2022-09-14 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
| CA3163608A1 (en) * | 2020-01-10 | 2021-07-15 | Romesh R. Subramanian | Muscle-targeting complexes and uses thereof |
| US20230285586A1 (en) * | 2020-07-23 | 2023-09-14 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
-
2022
- 2022-07-08 KR KR1020247004338A patent/KR20240035824A/ko active Pending
- 2022-07-08 AU AU2022309238A patent/AU2022309238A1/en active Pending
- 2022-07-08 EP EP22838594.4A patent/EP4366741A4/en active Pending
- 2022-07-08 JP JP2024500492A patent/JP2024525613A/ja active Pending
- 2022-07-08 US US18/577,452 patent/US20240368296A1/en active Pending
- 2022-07-08 CA CA3226367A patent/CA3226367A1/en active Pending
- 2022-07-08 MX MX2024000492A patent/MX2024000492A/es unknown
- 2022-07-08 WO PCT/US2022/073541 patent/WO2023283624A2/en not_active Ceased
- 2022-07-08 IL IL309912A patent/IL309912A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525611A5 (OSRAM) | ||
| JP2024525612A5 (OSRAM) | ||
| JP2024527362A5 (OSRAM) | ||
| JP2024525610A5 (OSRAM) | ||
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (OSRAM) | ||
| JP2023535073A5 (OSRAM) | ||
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| US20240325558A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| JP2023509793A5 (OSRAM) | ||
| JP2024540199A5 (OSRAM) | ||
| JP2024524222A5 (OSRAM) | ||
| JP2023512441A5 (OSRAM) | ||
| IL304048A (en) | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| IL322946A (en) | Methods and compositions for inhibiting the progression of intramuscular fibrosis |